Comparative Pharmacology
Head-to-head clinical analysis: CALAN versus CARDENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALAN versus CARDENE.
CALAN vs CARDENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
20-40 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker